{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 88,
  "pageCount": 93,
  "prevPage": 87,
  "nextPage": 89,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide presents preclinical efficacy data for a MALT1 inhibitor ('565) in combination with Ibrutinib.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/88",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-88",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.06,
        "y": 0.21
      },
      "kind": "chart",
      "text": "‘565 ± Ibrutinib in OCI-Ly10 Xenograft Model",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67046ad4-6a5a-4d7a-95bb-af23d558fb21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.52,
        "y": 0.21
      },
      "kind": "chart",
      "text": "‘565 ± Ibrutinib in TMD8 Xenograft Model",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94ff3a3b-2bf5-42f3-8468-68d6598dd0e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.06,
        "y": 0.68
      },
      "kind": "list",
      "text": "OCI-Ly10 cells are sensitive to both MALT1i and ibrutinib in vitro; Administration of ‘565 as a single agent showed tumour growth regression; Synergistic tumour growth observed when 10 mpk ‘565 was combined with ibrutinib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "702fa3ef-348e-4525-a3f0-daa636cc6622",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.52,
        "y": 0.68
      },
      "kind": "list",
      "text": "TMD8 DLBCL cells are sensitive to both MALT1i and ibrutinib in vitro, however, standalone administration of ibrutinib showed no activity in vivo; Significant synergistic efficacy was observed when ‘565 was combined with ibrutinib in the study; ‘565 was well tolerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fff6eecc-39ef-4c00-908e-88f0ea0dbc96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Payne et al. ESMO, 2023; OCI-Ly10 xenograft model: CD79A mutant; TMD8 xenograft model: CD79B mutant",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0787e738-3f9b-4ebe-9eda-d638281c89fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Single agent and synergistic effects seen in DLBCL xenograft models",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dab4d274-f1e3-4acf-8b80-2a9249762e9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565 inhibits DLBCL tumour model growth in vivo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41aa4626-6a3c-4b77-8283-e9f07ddb2134",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}